Search PubMed⌕ Search

Biomedical subjects

E W Monroe

Publications and source records attributed to E W Monroe.

26 records · Page 2Linked to original sources
PubMed1976

Vitiligo associated with regional enteritis.

Although the cause of vitiligo is unknown, there is considerable evidence to indicate that autoimmunity plays a role. Much of this evidence is based on the increased associated occurrence of vitiligo in a number of diseases also believed to be autoimmune in origin. I have observed a case of almost simultaneous onset of vitiligo and regional enteritis. A search of the literature revealed no specific case report associating these two disorders. The association of these two disorders in the same person may be more than fortuitous, since both diseases may be autoimmune in origin.

Adult↗
PubMedDate not supplied

Loratadine in the treatment of urticaria.

Urticaria is a common skin disease, which in its chronic form, is a very disturbing condition. Because histamine is the best-documented chemical mediator of urticaria, histamine-antagonists are the mainstay of therapy. First-generation antihistamines are limited by their tendency to produce sedation and anticholinergic side effects. Most of the newer second generation antihistamines compare well with the earlier agents in efficacy but are not limited by the same adverse side effects. Loratadine may be distinguished from other second-generation antihistamines by its pharmacodynamic profile, as well as its tolerability and safety.

Arrhythmias, Cardiac↗
PubMedDate not supplied

Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.

Topical corticosteroids and keratolytics are both used widely in the management of patients with psoriasis. A combination of the two types of agents may provide enhanced relief. The purpose of this study was to compare the efficacy and safety of the combination ointment mometasone furoate 0.1% plus salicylic acid 5% with that of mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis vulgaris. A total of 408 patients were enrolled in this controlled, randomized, double-masked, parallel-group, multicenter comparison. Patients applied either mometasone furoate-salicylic acid ointment or mometasone furoate ointment alone to target lesions twice daily for 21 days. Severity of erythema, induration, and scaling were scored at baseline and at days 4, 8, 15, and 22. An evaluation of overall change in disease status of all treated lesions was performed at each follow-up visit. Adverse events were also monitored and scored, including signs of skin atrophy. Beginning on day 8, the combination of mometasone furoate-salicylic acid was significantly more effective than mometasone furoate alone, as indicated by the mean percentage of improvement in total disease scores, mean total disease sign scores, and the individual score for scaling. Similarly, the combination was more effective beginning on day 15, as indicated by the global evaluation of overall clinical response and individual scores for erythema and induration. Both treatments were well tolerated. Mometasone furoate-salicylic acid ointment provides more effective treatment of moderate-to-severe psoriasis than does mometasone furoate ointment alone and is safe and well tolerated.

Administration, Topical↗
PubMedDate not supplied

Urticaria.

Explore the source record for details and available documents.

Adolescent↗
PubMedDate not supplied

Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis.

The subjects of this double-blind study were 59 patients with chronic idiopathic urticaria or atopic dermatitis randomly assigned to receive 10 mg of loratadine once daily and placebo twice daily (n = 20), 25 mg of hydroxyzine thrice daily (n = 20), or placebo thrice daily (n = 19). The patients (15 men, 44 women) were aged 18 to 65 years. Among the 18 patients with urticaria and 41 with atopic dermatitis, daily symptom scores decreased 43% and 57% in those receiving loratadine, 47% and 38% in those receiving hydroxyzine, and 0% and 33% in the placebo patients. The difference between the treated and placebo patients was significant among the urticaria patients. According to a global evaluation of treatment effects, more treated than placebo patients reported marked or complete symptom relief; among the patients with atopic dermatitis, the difference was significant between the loratadine and placebo patients. Somnolence or sedation during treatment was reported by one of the patients receiving loratadine, by eight of the hydroxyzine patients, and by two of the placebo patients; the difference between the loratadine and hydroxyzine patients was significant. It was concluded that loratadine is as effective as hydroxyzine in the treatment of urticaria and demonstrates a significant antipruritic effect in atopic dermatitis, but does not have the central nervous system effects of hydroxyzine.

Adolescent↗